On July 8, 2025, Personalis, Inc. amended an agreement with Tempus AI, Inc. to allow marketing of their NeXT Personal® test for colorectal cancer, extending the agreement until November 2029 and establishing exclusivity until December 31, 2028.
AI Assistant
PERSONALIS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.